CClinicalTrials.gg
CompletedNCT01958853PERRFECTUpdated Sep 17, 2015

Prospective Evaluation of Reduced Impedance Noninvasive Cortical Electrostimulation (RINCE) to Reduce Fibromyalgia Effects - Extension Study

An interventional study of RINCE in Fibromyalgia, sponsored by Cerephex Corporation. Completed at 1 site in United States. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-09-17.

Sponsored by Cerephex Corporation · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
22 Years to 65 Years
Sex
All
01

Study summary

The purpose of this open label study is to provide up to 24 active treatments of noninvasive cortical electrostimulation therapy only to those fibromyalgia patients who experienced inadequate pain reduction in a sham controlled double blinded lead in study, NPT-201 (NCT01825954). The therapy will be provided by the NeuroPoint device using the same protocol as that used in active treatment arms of NPT-201. The study's primary outcome measure will be the patient's change from baseline in self-reported 24-hour average pain intensity. The study will provide active treatment to those participants who received sham therapy in NPT-201, and will test whether or not additional therapy applications might further improve pain in those participants who previously received active therapy, but did not achieve adequate pain relief.

02

Conditions studied

  • Fibromyalgia

Keywords

  • Pain
03

In context

Fibromyalgia

1,335 studies on the registry are indexed under Fibromyalgia; 265 are open to participants now.

This study's enrollment of 23 is below the median of 60 across 1,034 interventional studies indexed under Fibromyalgia.

Browse Fibromyalgia studies →

Lead sponsor

Cerephex Corporation is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patient must have successfully completed study NPT-201 and had an inadequate pain response, defined as \<50% reduction in pain from baseline during participation in NPT-201.
  • Patient must provide written informed consent and privacy authorization prior to participation in the study.
  • Female patients of childbearing potential must be willing to use an acceptable method of birth control for the duration of their study participation. Acceptable birth control includes a vasectomized partner, contraceptives (oral, parenteral, or transdermal), intrauterine device, or double barrier method including condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream. Patients considered not of childbearing potential must be surgically sterile (total hysterectomy, bilateral salpingo-oophorectomy, or tubal ligation) or greater than one year post-menopausal, defined as a complete cessation of menstruation for at least one year.
  • Patients must be willing to refrain from all excluded therapies for the duration of the study.
  • In the opinion of the Investigator, the patient is willing and able to comply with all protocol-specified requirements.

Exclusion criteria

Exclusion Criteria:

  • Patient has a current significant psychological or psychiatric disorder (e.g., severe, unstable or poorly controlled depression, severe anxiety or obsessive-compulsive disorder.
  • Patient has a score of 2 or 3 on item 9 of the BDI, or, based on the investigator's judgment, the patient is at risk of suicidal ideation or behavior.
  • Patient has resumed treatment with duloxetine, milnacipran, pregabalin, gabapentin, sodium oxybate or prohibited narcotics.
  • Female patient who is pregnant, planning a pregnancy, or breastfeeding.
  • Any anticipated need for surgery that might confound results or interfere with patient's ability to comply with the protocol.
  • The occurrence of a major protocol violation during the lead-in study indicating a lack of compliance or other significant concern that precludes the patient's ongoing participation.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    12-week RINCE

    RINCE - active RINCE therapy involving 24 total treatment applications from the NeuroPoint device

    Device: RINCE

Interventions

  • DeviceRINCE

    The NeuroPoint device is used to deliver repeat applications of RINCE therapy

    Also known as: RINCE therapy, RINCE therapy using the NeuroPoint device

06

What researchers measure

Primary outcomes

  1. Change from baseline in patient 24-hour recall average pain intensity

    Pain intensity evaluated on a 100-mm visual analog scale (VAS)

    Time frame: Assessed at 12 weeks

Secondary outcomes

  1. Patient self-reported Global Impression of Change

    Time frame: Assessed at 12 weeks

  2. Change from baseline in Revised Fibromyalgia Impact Questionnaire

    Time frame: Assessed at 12 weeks

  3. Change from baseline in patient 7-day recall average pain intensity

    Time frame: Assessed at 12 weeks

  4. Change from baseline in Jenkins Sleep Questionnaire

    Time frame: Assessed at 12 weeks

Other outcomes

  1. Change from baseline in Beck Depression Inventory (BDI-II)

    Time frame: Assessed at 12 weeks

07

Study locations

1 site
  • St. Joseph Mercy Oakland
    Pontiac, Michigan 48341, United States
08

References and documents

Publications

  • Hargrove JB, Bennett RM, Simons DG, Smith SJ, Nagpal S, Deering DE. A randomized placebo-controlled study of noninvasive cortical electrostimulation in the treatment of fibromyalgia patients. Pain Med. 2012 Jan;13(1):115-24. doi: 10.1111/j.1526-4637.2011.01292.x. PubMed 22233397 ↗
  • Hargrove JB, Bennett RM, Clauw DJ. Long-term outcomes in fibromyalgia patients treated with noninvasive cortical electrostimulation. Arch Phys Med Rehabil. 2012 Oct;93(10):1868-71. doi: 10.1016/j.apmr.2012.04.006. Epub 2012 Apr 21. PubMed 22525670 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 17, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01958853
Lead sponsor
Cerephex Corporation
Responsible party
Sponsor
First posted
Oct 9, 2013
Start date
Aug 2013
Primary completion
May 2014
Completion
May 2014
Last update
Sep 17, 2015

Study contacts

Donald E Deering, PhD
principal investigator · St. Joseph Mercy Oakland
Jeffrey B Hargrove, PhD
principal investigator · Cerephex Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion